These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24643574)

  • 1. Cost-effectiveness analysis comparing conventional versus stereotactic body radiotherapy for surgically ineligible stage I non-small-cell lung cancer.
    Mitera G; Swaminath A; Rudoler D; Seereeram C; Giuliani M; Leighl N; Gutierrez E; Dobrow MJ; Coyte PC; Yung T; Bezjak A; Hope AJ
    J Oncol Pract; 2014 May; 10(3):e130-6. PubMed ID: 24643574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer.
    Shah A; Hahn SM; Stetson RL; Friedberg JS; Pechet TT; Sher DJ
    Cancer; 2013 Sep; 119(17):3123-32. PubMed ID: 23720093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer.
    Paix A; Noel G; Falcoz PE; Levy P
    Radiother Oncol; 2018 Sep; 128(3):534-540. PubMed ID: 29706462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer.
    Haque W; Verma V; Polamraju P; Farach A; Butler EB; Teh BS
    Radiother Oncol; 2018 Nov; 129(2):264-269. PubMed ID: 30031630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer.
    Lanni TB; Grills IS; Kestin LL; Robertson JM
    Am J Clin Oncol; 2011 Oct; 34(5):494-8. PubMed ID: 20805737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of stereotactic body radiotherapy versus conventional radiotherapy for the treatment of surgically ineligible stage I non-small cell lung cancer in the Brazilian public health system.
    Arruda GV; Lourenção M; de Oliveira JHC; Galendi JSC; Jacinto AA
    Lancet Reg Health Am; 2022 Oct; 14():100329. PubMed ID: 36777381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis.
    Puri V; Crabtree TD; Kymes S; Gregory M; Bell J; Bradley JD; Robinson C; Patterson GA; Kreisel D; Krupnick AS; Meyers BF
    J Thorac Cardiovasc Surg; 2012 Feb; 143(2):428-36. PubMed ID: 22169443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Definitive Radiotherapy for Inoperable Stage IIB Non-small-cell Lung Cancer: Patterns of Care and Comparative Effectiveness.
    Jacobs CD; Gao J; Wang X; Clarke JM; Tong B; Ready NE; Suneja G; Kelsey CR; Torok JA
    Clin Lung Cancer; 2020 May; 21(3):238-246. PubMed ID: 31757764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer.
    van den Hout WB; Kramer GW; Noordijk EM; Leer JW
    J Natl Cancer Inst; 2006 Dec; 98(24):1786-94. PubMed ID: 17179480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
    Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
    Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer.
    Sher DJ; Wee JO; Punglia RS
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e767-74. PubMed ID: 21300476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients.
    Ramaekers BL; Joore MA; Lueza B; Bonastre J; Mauguen A; Pignon JP; Le Pechoux C; De Ruysscher DK; ; Grutters JP
    J Thorac Oncol; 2013 Oct; 8(10):1295-307. PubMed ID: 24457241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison Between Stereotactic and Conventional Radiotherapy for Solitary Lung Tumor After Resection of Lung Cancer.
    Takahashi S; Go T; Anada M; Kinoshita T; Nishide T; Yokomise H; Shibata T
    Anticancer Res; 2019 Jun; 39(6):2957-2962. PubMed ID: 31177135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study.
    Wolff HB; Alberts L; van der Linden N; Bongers ML; Verstegen NE; Lagerwaard FJ; Hofman FN; Uyl-de Groot CA; Senan S; El Sharouni SY; Kastelijn EA; Schramel FMNH; Coupé VMH
    Lung Cancer; 2020 Mar; 141():89-96. PubMed ID: 31982640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial.
    Ricardi U; Filippi AR; Guarneri A; Giglioli FR; Ciammella P; Franco P; Mantovani C; Borasio P; Scagliotti GV; Ragona R
    Lung Cancer; 2010 Apr; 68(1):72-7. PubMed ID: 19556022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial.
    Swaminath A; Wierzbicki M; Parpia S; Wright JR; Tsakiridis TK; Okawara GS; Kundapur V; Bujold A; Ahmed N; Hirmiz K; Kurien E; Filion E; Gabos Z; Faria S; Louie AV; Owen T; Wai E; Ramchandar K; Chan EK; Julian J; Cline K; Whelan TJ
    Clin Lung Cancer; 2017 Mar; 18(2):250-254. PubMed ID: 27876603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
    Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
    Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational Status.
    Kim H; Vargo JA; Ling DC; Beriwal S; Smith KJ
    Am J Clin Oncol; 2019 Nov; 42(11):837-844. PubMed ID: 31644441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What if a tumor is significantly enlarged just before stereotactic body radiation therapy? A case report and review of the literature.
    Chen HJ; Liang JA; Chen CY; Yu YH; Chien CR
    Thorac Cancer; 2017 Mar; 8(2):118-120. PubMed ID: 28102933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiotherapy versus surgery for medically operable Stage I non-small-cell lung cancer: a Markov model-based decision analysis.
    Louie AV; Rodrigues G; Hannouf M; Zaric GS; Palma DA; Cao JQ; Yaremko BP; Malthaner R; Mocanu JD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):964-73. PubMed ID: 20932688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.